230 related articles for article (PubMed ID: 31852781)
21. Evolution of the Envelope Glycoprotein of HIV-1 Clade B toward Higher Infectious Properties over the Course of the Epidemic.
Bouvin-Pley M; Beretta M; Moreau A; Roch E; Essat A; Goujard C; Chaix ML; Moiré N; Martin L; Meyer L; Barin F; Braibant M
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567994
[TBL] [Abstract][Full Text] [Related]
22. Antibodies to several conformation-dependent epitopes of gp120/gp41 inhibit CCR-5-dependent cell-to-cell fusion mediated by the native envelope glycoprotein of a primary macrophage-tropic HIV-1 isolate.
Verrier FC; Charneau P; Altmeyer R; Laurent S; Borman AM; Girard M
Proc Natl Acad Sci U S A; 1997 Aug; 94(17):9326-31. PubMed ID: 9256481
[TBL] [Abstract][Full Text] [Related]
23. SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement.
Alsahafi N; Anand SP; Castillo-Menendez L; Verly MM; Medjahed H; Prévost J; Herschhorn A; Richard J; Schön A; Melillo B; Freire E; Smith AB; Sodroski J; Finzi A
J Virol; 2018 Oct; 92(19):. PubMed ID: 30021898
[TBL] [Abstract][Full Text] [Related]
24. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
25. HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
Yang E; Gardner MR; Zhou AS; Farzan M; Arvin AM; Oliver SL
PLoS One; 2018; 13(10):e0206365. PubMed ID: 30359435
[TBL] [Abstract][Full Text] [Related]
26. Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers.
Castillo-Menendez LR; Witt K; Espy N; Princiotto A; Madani N; Pacheco B; Finzi A; Sodroski J
J Virol; 2018 Jun; 92(12):. PubMed ID: 29618643
[TBL] [Abstract][Full Text] [Related]
27. Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.
Jiang X; Totrov M; Li W; Sampson JM; Williams C; Lu H; Wu X; Lu S; Wang S; Zolla-Pazner S; Kong XP
J Virol; 2016 Dec; 90(24):11007-11019. PubMed ID: 27707920
[TBL] [Abstract][Full Text] [Related]
28. Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection.
Beitari S; Pan Q; Finzi A; Liang C
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493821
[TBL] [Abstract][Full Text] [Related]
29. A 2-4-Amino Acid Deletion in the V5 Region of HIV-1 Env gp120 Confers Viral Resistance to the Broadly Neutralizing Human Monoclonal Antibody, VRC01.
Tachibana S; Sasaki M; Tanaka T; Inoue M; Ophinni Y; Kotaki T; Kameoka M
AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1248-1257. PubMed ID: 28903577
[TBL] [Abstract][Full Text] [Related]
30. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
[TBL] [Abstract][Full Text] [Related]
31. Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.
Esser MT; Mori T; Mondor I; Sattentau QJ; Dey B; Berger EA; Boyd MR; Lifson JD
J Virol; 1999 May; 73(5):4360-71. PubMed ID: 10196334
[TBL] [Abstract][Full Text] [Related]
32. Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.
Frey G; Rits-Volloch S; Zhang XQ; Schooley RT; Chen B; Harrison SC
Proc Natl Acad Sci U S A; 2006 Sep; 103(38):13938-43. PubMed ID: 16963566
[TBL] [Abstract][Full Text] [Related]
33. Role of envelope processing and gp41 membrane spanning domain in the formation of human immunodeficiency virus type 1 (HIV-1) fusion-competent envelope glycoprotein complex.
Welman M; Lemay G; Cohen EA
Virus Res; 2007 Mar; 124(1-2):103-12. PubMed ID: 17129629
[TBL] [Abstract][Full Text] [Related]
34. Kinetic studies of HIV-1 and HIV-2 envelope glycoprotein-mediated fusion.
Gallo SA; Reeves JD; Garg H; Foley B; Doms RW; Blumenthal R
Retrovirology; 2006 Dec; 3():90. PubMed ID: 17144914
[TBL] [Abstract][Full Text] [Related]
35. Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins.
Herschhorn A; Ma X; Gu C; Ventura JD; Castillo-Menendez L; Melillo B; Terry DS; Smith AB; Blanchard SC; Munro JB; Mothes W; Finzi A; Sodroski J
mBio; 2016 Oct; 7(5):. PubMed ID: 27795397
[TBL] [Abstract][Full Text] [Related]
36. The effect of the membrane-proximal tyrosine-based sorting signal of HIV-1 gp41 on viral infectivity depends on sequences within gp120.
Day JR; Van Damme N; Guatelli JC
Virology; 2006 Oct; 354(2):316-27. PubMed ID: 16905171
[TBL] [Abstract][Full Text] [Related]
37. Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.
Espy N; Pacheco B; Sodroski J
Virology; 2017 Aug; 508():90-107. PubMed ID: 28521215
[TBL] [Abstract][Full Text] [Related]
38. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
39. Targeting therapeutics to an exposed and conserved binding element of the HIV-1 fusion protein.
Root MJ; Hamer DH
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5016-21. PubMed ID: 12702763
[TBL] [Abstract][Full Text] [Related]
40. Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop.
Wang H; Cohen AA; Galimidi RP; Gristick HB; Jensen GJ; Bjorkman PJ
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7151-E7158. PubMed ID: 27799557
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
